Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 251 - 300 out of 110,649

Document Document Title
WO/2016/032249A1
The present invention relates to a pharmaceutical composition and a food composition containing Vaccinium bracteatum Thunb. extract or a fraction thereof as an active ingredient for preventing, treating or ameliorating neuroinflammation ...  
WO/2016/030306A1
The present invention relates to a compound of formula (I) wherein R1/R2 are independently from each other hydrogen or halogen; L is a bond, -NH-, -C(O)NH-, -NHC(O)- or NHC(O)NH-; R is hydrogen, lower alkyl, cycloalkyl, benzyl, phenyl or...  
WO/2016/029454A1
Provided are quinoline carboxamide and quinoline carbonitrile compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 1, R 2, L, X 1, X 2, and X 3, are as defined herein. The compounds of the invention, and phar...  
WO/2016/032569A1
Provided herein are quinolines, e.g., a compound of Formula (I) or (IB), pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of an endoplasmic reticulum stress-caus...  
WO/2016/030345A1
The invention relates to a product that comprises a compound of formula (1-01) to (1-47) and a compound of formula (2-01) to (2-26),or their pharmaceutically or veterinary acceptable salts thereof, or any stereoisomers either of the comp...  
WO/2016/029669A9
The present invention relates to a photo-hexyl ether compound, and a pharmaceutical composition and usage thereof. Particularly, the present invention relates to 2(4)-(1-hexyloxyethyl)-6,7-dipropionate-1,3,5,8-tetramethyl- 4(2)-vinylporp...  
WO/2016/031987A1
A compound represented by any of formulas (Ia)-(Ic) or formula (II), or a pharmaceutically acceptable salt thereof. (In the formulas, R1, R2, R3, R4a, R4c, R5, R15, ring A, X1, and X2 are as defined in the specification.)  
WO/2016/030444A1
The present invention provides a novel chromone oxime derivative of formula (I), which is a modulator of nervous system receptors sensitive to glutamate and, furthermore, presents an advantageously high brain penetration upon oral admini...  
WO/2016/033326A3
Disclosed herein are methods for reducing or arresting an increase in a Neuropathy Impairment Score (NIS) or a modified NIS (mNIS+7) in a human subject by administering an effective amount of a transthyretin (TTR)-inhibiting composition.  
WO/2016/033100A1
In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting ...  
WO/2016/031742A1
[Problem] To provide a medicine useful for the amelioration of paresthesia induced by peripheral nerve disorders. [Solution] An extract from a plant belonging to the genus Plantago (e.g., a Plantago seed, a Plantago herb) is useful for t...  
WO/2016/029669A1
The present invention relates to a photo-hexyl ether compound, and a pharmaceutical composition and usage thereof. Particularly, the present invention relates to 2(4)-(1-hexyloxyethyl)-6,7-dipropionate-1,3,5,8-tetramethyl- 4(2)-vinylporp...  
WO/2016/031264A1
The present invention addresses the problem of providing a new therapeutic strategy for an ailment wherein skeletal muscle loss is the main cause or partial cause of the ailment. Provided is a skeletal muscle bulking agent containing mec...  
WO/2016/030443A1
Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.  
WO/2016/030310A1
The present invention relates to a compound of formula I wherein R1 is hydrogen, methoxy or fluoro; R2/R2' are independently from each other hydrogen, methoxy or fluoro; R3/R4 are independently from each other hydrogen or halogen; R is h...  
WO/2016/029310A1
The present disclosure relates to indole derivatives of the formula (I) which are cannabinoid type 1 receptor modulators and which are useful in the treatment of diseases in which modulation of the receptor is beneficial; to processes fo...  
WO/2016/031839A1
This invention prevents and/or treats vitamin B1 deficiency caused when administering a large dose of a pyridoxamine compound. A pharmaceutical composition is administered, the pharmaceutical composition formed by combining at least one ...  
WO/2016/032250A1
The present invention relates to a pharmaceutical composition and a food composition containing Portulaca grandiflora Hook. extract or a fraction thereof as an active ingredient for preventing, treating or ameliorating neuroinflammation ...  
WO/2016/029888A1
The present invention provides amphiphilic compounds with tetradecahydrophenanthrene skeleton and their enantiomers, exhibiting neuroprotective effects, their use as medicaments for treating neuropsychiatric disorders associated with an ...  
WO/2016/030522A1
The present invention relates to compositions and methods for the treatment of Parkinson's disease and related disorders. More specifically, the present invention relates to novel combinatorial therapies of Parkinson's disease and relate...  
WO/2016/026041A1
The present invention relates to a buccal delivery dosage form and its use for administration of a therapeutic gas for buccal mucosal absorption of the therapeutic gas in the mouth of a subject. The buccal delivery dosage form comprises ...  
WO/2016/028971A1
The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This inven...  
WO/2016/027224A1
A pharmaceutical composition or dietary supplement is described that is effective in the treatment of neuropathies and/or neuropathic pain, comprising, as the active ingredients, a combination of curcumin, N-acetyl-L-carnitine and alpha-...  
WO/2016/026978A1
The present invention relates to methods and pharmaceutical compositions for treating drug addiction, preferably alcoholism, ecstasy addiction or cocaine addiction, in a subject in need thereof. In particular, the present invention relat...  
WO/2016/027276A1
The present invention is directed to active metabolite of 1-[(2- bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)m ethyl]-1H-indole dimesylate monohydrate having the following structure The present invention is also directed t...  
WO/2016/027754A1
In order to provide an agent for the prevention and/or treatment of Trk-related diseases, the present invention provides a compound that has selective inhibitory activity on Trk, persistently suppresses NGF vascular hyperpermeability, ha...  
WO/2016/027757A1
The present invention addresses the problem of providing a novel compound for realizing an effect on a therapeutic and/or preventive drug for mental illnesses, such as depression, atypical depression, treatment-resistant depression, anxi...  
WO/2016/026016A1
The present invention relates to an opioid peptide represented by general formula TyrProPhe-X1-TrpGlyGly-X2-ProPro, where: X1 stands for Gly or Lys; X2 stands for Ile or Val. The invention also relates to pharmaceutical, nutritional and ...  
WO/2016/026078A1
Compounds of Formula (I) and pharmaceutical compositions containing the compounds are disclosed, which are used for treatment of disease, disorder or condition associated with ERK activity.  
WO/2016/026017A1
The present invention relates to an opioid peptide represented by general formula TyrGlyGly-X1-X2-X3-X4, where: X1 stands for Thr or Glu; X2 stands for Gly, Thr or Ala; X3 stands for Ala, Val, Gly or Glu; and X4 stands for His, Gln, Thr,...  
WO/2016/027089A1
The present invention relates to conjugates of cyclosporin with quinolium mitochondrial targeting groups, and their therapeutic uses.  
WO/2016/027253A1
Disclosed is a method of treating a RIP1 kinase-mediated disease or disorder which comprises administering a therapeutically effective amount of a compound that inhibits RIP1 kinase and at least one other therapeutically active agent to ...  
WO/2016/026772A1
Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises the following formula (I): wherein X1 is selected from C and N; X3 and X5 may be the...  
WO/2016/028910A1
A link between ApoE4 allele and sirtuins expression level is identified that is believed to be associated with elevated risk for the promotion of processing of amyloid precursor protein (APP) by the non-amyloidogenic pathway in a mammal ...  
WO/2016/027844A1
A compound represented by formula (I) or a pharmaceutically acceptable salt thereof. (In the formula, R represents a methyl group or the like; R1 represents a fluorine atom or the like; R2 represents a hydrogen atom or a fluorine atom; R...  
WO/2016/027168A2
A splice modulating oligonucleotide (SMO), is provided having a sequence designed to modulate the splicing of a SCN8A pre-mRNA, wherein the SMO sequence specifically binds to a sequence in the SCN8A pre-mRNA. Certain embodiments of the i...  
WO/2016/027241A1
The invention relates to a compound of formula (I) wherein X1 to X4 and RC to RG are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.  
WO/2016/027168A3
A splice modulating oligonucleotide (SMO), is provided having a sequence designed to modulate the splicing of a SCN8A pre-mRNA, wherein the SMO sequence specifically binds to a sequence in the SCN8A pre-mRNA. Certain embodiments of the i...  
WO/2016/028811A1
A composition for relieving pain, and methods of making and using the composition, whereby the composition comprises an amount of sugar or sugar alcohol; and an amount of vehicle; wherein the composition is formulated for transdermal adm...  
WO/2016/027259A1
The present invention is directed to pharmaceutical compositions and methods of use. The pharmaceutical compositions comprise a central nervous system (CNS) active agent and pseudoephedrine (PSE), phenylephrine (PHE), or both. In some em...  
WO/2016/025829A1
Provided are therapeutic agents such as double-stranded nucleic acids, termed oligonucleotide decoys, pharmaceutical compositions comprising the same, and related methods of modulating nociceptive signaling, for instance, to prevent and/...  
WO/2016/025533A3
In some aspects, described herein are methods of treating synucleinopathies using FK506.  
WO/2016/023997A1
The present invention relates to a chemical compound having the general formula (I): wherein R1 and R2 are, equal or independently, aryl, heteroaryl; wherein RTA is a 2-1,3-, or 4- 1,3- or 5-1,3-thiazole ring and its use in for improving...  
WO/2016/025745A9
A dendrimer formation, such as a PAMAM dendrimer or a multiarm PEG polymeric formulation has been developed for systemic administration to the brain or central nervous system. In the preferred embodiment, the dendrimers are in the form o...  
WO/2016/025721A1
This disclosure provides methods and regimens for treating depression (e.g., treatment-resistant depression) in a patient (e.g., a patient in need of such treatment).  
WO/2016/025904A1
The present invention relates to crystalline forms of the compound represented by Structural Formula I, and compositions comprising crystalline forms of the compound represented by Structural Formula I described herein. The crystalline f...  
WO/2016/023108A1
Drug delivery formulations useful to prevent or reduce purposeful or accidental overdose of a drug, and methods of making the same are provided. The formulations comprise either an alkalinizing coat in an amount sufficient to raise the p...  
WO/2016/025424A1
The present invention provides compounds having the general structural formula (I) (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceut...  
WO/2016/023830A1
This invention relates to novel Pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione derivatives of Formula (I) and their use as TRPC5 modulators, pharmaceutical compositions containing the same, and methods of using the same as agents for the treat...  
WO/2016/025778A1
The present invention relates to the field of seizures. More specifically, the present invention provides compositions and methods for treating refractory seizures in neonates. In one embodiment, the method comprises the steps of (a) adm...  

Matches 251 - 300 out of 110,649